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| INTRODUC TI ON
Coronary artery disease (CAD) is a global health concern that accounts for approximately one-third of all deaths in individuals older than 35 years. [1] [2] [3] In order to decrease the mortality of CAD, various treatment approaches have been raised, such as calcium channel blockers, β-receptor blocks, antithrombotic treatment, percutaneous coronary intervention (PCI), and coronary artery bypass graft. 1 Among these treatment approaches, PCI with drug-eluting stents (DES) is one of the most widely performed procedures for the treatment of CAD, which obviously reduces the acute vascular closure and the risk of repeat revascularization. 4 However, a number of CAD patients still occur in-stent restenosis of target artery and rapid angiographic stenotic progression (RASP) of non-intervened lesion after underwent PCI with DES, which pronouncedly decrease the long-term outcomes of these patients. 5, 6 Therefore, investigating valuable biomarkers for predicting restenosis and RASP is of great importance to optimize the treatment schedule and improve the prognosis of CAD patients underwent PCI with DES.
Accumulating evidences suggest that inflammatory reactions play important roles in the development and progression of restenosis; however, seldom studies investigate the predictive value of specific inflammatory factors for risk of restenosis or RASP, only a study discovers that HsCRP is able to predict the increased risk of restenosis and RASP in CAD patients underwent PCI with DES. 7, 8 As the most common inflammatory factors, inflammatory cytokines (including TNF-α, IL-1, IL-6, and so on) exert multiple functions (such as promote leukocyte recruitment, monocyte chemotaxis, and oxidative stress) in endothelial cells, thereby mediate the inflammation reactions and induce the neointimal hyperplasia (such as smooth muscle proliferation/migration, extracellular matrix deposition) and vessel remodeling in CAD patients. 2, 9 In addition, several inflammatory cytokines (such as IL-6 and IL-18) are also discovered to be associated with elevated risk of CAD. 2, 10, 11 Considering all the evidences above, we hypothesized that some inflammatory cytokines might be able to predict restenosis and RASP risk in CAD patients underwent PCI with DES. Therefore, this study aimed to explore the associations of nine common pre-operative inflammatory cytokine expressions with restenosis and RASP risk in CAD patients underwent PCI with DES.
| MATERIAL S AND ME THODS

| Patients
Two hundred and ten CAD patients underwent PCI treatment with sirolimus-eluting stent at our hospital were consecutively recruited as study subjects, between January 2015 and May 2018. The patients were enrolled if they met the following inclusion criteria:
(a) diagnosed as CAD according to angiographic demonstration; (b) about to undergo PCI with DES implantation; (c) no clinical contraindications to PCI and no anaphylaxis to sirolimus-eluting stents;
and (d) age ≥18 years old. The exclusion criteria were as follows: (a) history of cardiovascular surgery (such as PCI, revascularization, or coronary artery bypass grafting); (b) complicated with inflammatory diseases, autoimmune diseases, or hematologic malignancies;
(c) history of severe infection or malignant tumors; (d) treatment with anti-inflammatory drugs or immunosuppressive drugs within 3 months before enrollment; (e) unable to be followed up regularly;
and (f) pregnant or lactating women. The study was approved by the Institutional Review Board of ZiBo Central Hospital. All patients provided written informed consents at the time of enrollment.
| Data collection
After enrollment, the clinical data of patients were recorded, which included (a) demographic characteristics: age, gender and body mass index (BMI); (b) CAD risk factors: current smoke status, hypertension, diabetes mellitus, hypercholesteremia, hyperuricemia, and family his- (g) drugs used after PCI: aspirin, clopidogrel, nitrates, statins, β-receptor blockers, angiotensin-converting enzymes inhibitors/angiotensin receptor blockers (ACEIs/ARBs), and calcium channel blockers.
| Sample collection and detection
Peripheral blood samples of patients were collected in the coagulation tube before PCI treatment, and then, the serum was centrifuged at the condition of 2500 g, 15 minutes (4°C). After separation, the serum was stored at −80°C until determination. The levels of inflammatory cytokines in serum including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-4, IL-6, IL-8, IL-10, IL-17A, IL-21, and IL-23 were determined by enzyme-linked immunosorbent assay (ELISA) using commercial human ELISA Kits (eBioscience) following the manufacturer's protocol.
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| Assessment of in-stent restenosis and RASP
The PCI procedures, the implantation of sirolimus-eluting stent (Lepu (Beijing) Medical Devices Co., Ltd) as well as the pre-operative and postoperative management (eg, the management of aspirin, clopidogrel, and so on) were performed as recommended by the PCI guideline. 12 Coronary angiography was conducted before PCI, immediately post PCI and at 12-month follow-up (or earlier if clinically indicated), and the in-stent restenosis and RASP of nonintervened lesion were assessed by the quantitative coronary angiography (QCA) analysis. The QCA analysis was performed on the computer-based system Cardiovascular Angiographic Analysis System (CAAS) II (Pie Medical, Maastricht, the Netherlands), which was used as previously described. 13, 14 The diameter function of the coronary artery lumen was determined by computing the shortest distance between the edge points of the right and left boundaries. 
| Sample size calculation
In this study, sample size calculation was based on the level of TNF-α between patients with restenosis and patients without restenosis in our pilot study, using PASS V11.0 software (NCSS). In the pilot study, a total of 10 eligible patients were recruited, including five patients developed restenosis after PCI with sirolimus-eluting stent and five patients without restenosis after PCI with sirolimus-eluting stent. The TNF-α mean level of 10 patients was restenosis patients: 50.7 ± 30.9 pg/mL and patients without restenosis: 34.0 ± 20.7 pg/ mL. As reported in the previous study, 7 the restenosis occurrence was 21.0%. Hence, the hypothetical sample ratio of restenosis patients and non-restenosis patients was 1:4. Using the TNF-α mean level of restenosis patients (50.7 ± 30.9) and patients without restenosis (34.0 ± 20.7), a sample ratio of 1:4, a power of 85%, a two-sided 5% level of significance (α), and a two-sample t test, the required sample size was 180. In order to ensure the analysis power, the minimum sample size should be 180, meanwhile, taking a 15% attrition rate into account, the sample size was increased to 210 finally. 
| Statistical analysis
| RE SULTS
| Characteristics of CAD patients
Among the 210 CAD patients, there were 11 patients who lost follow-up and did not have restenosis assessment. Thus, we regarded these 11 patients as patients without restenosis and RASP. In this study, 54 were restenosis patients and 156 were non-restenosis patients; meanwhile, 88 were RASP patients and the other 122 were non-RASP patients (Detailed characteristics were shown in Table 1 ). For the comparison between restenosis patients and non-restenosis patients, the percentages of patients with hypertension (P = 0.016), diabetes mellitus (P = 0.028), and multivessel artery lesions (P = 0.049) were higher in restenosis TA B L E 1 (Continued) (P < 0.001), cTnl level (P = 0.045), and HsCRP level (P < 0.001) were elevated whereas the HDL-C level (P = 0.029) was declined in RASP patients compared with non-RASP patients. As to demographic (all P > 0.05) and other clinical characteristics (all P > 0.05), they were similar between RASP patients and non-RASP patients ( Table 1 ).
| Comparison of pre-operative inflammatory cytokine expressions between restenosis and nonrestenosis patients
The pre-operative expressions of TNF-α (P = 0.002, Figure 1A ), IL-6 (P < .001, Figure 1D ), IL-17A (P < 0.001, Figure 1G ), and IL-23
(P = 0.004, Figure 1I ) were increased, while the pre-operative IL-4 (P = 0.013, Figure 1C ) expression was decreased in restenosis patients compared with non-restenosis patients. As for pre-operative IL-1β (P = 0.369, Figure 1B ), IL-8 (P = 0.079, Figure 1E ), IL-10 (P = 0.362, Figure 1F ), and IL-21 (P = 0.127, Figure 1H ) expressions, they were similar between restenosis patients and non-restenosis patients.
| Analysis of inflammatory cytokines affecting restenosis risk
Univariate logistic regression analysis was conducted to investigate the inflammatory cytokines affecting restenosis risk, which dis- (P = 0.014) and IL-8 (P = 0.040) expressions were independent risk factors for restenosis. Hypercholesteremia (P = 0.002), diabetes mellitus (P = 0.001), and HsCRP (P < 0.001) could also independently predict restenosis risk ( Table 2 ).
| Predicting values of potential factors for restenosis risk
To further explore the predicting values of IL-6, IL-8, HsCRP, hypercholesteremia, and diabetes mellitus for restenosis risk, ROC curves were drawn, which showed that the AUCs were 
| Comparison of pre-operative inflammatory cytokine levels between RASP and non-RASP patients
Pre-operative expressions of TNF-α (P < 0.001, Figure 3A ), IL-6 (P < 0.001, Figure 3D ), IL-17A (P < 0.001, Figure 3G ), IL-21 (P = 0.006, Figure 3H ), and IL-23 (P < 0.001, Figure 3I ) were increased, whereas pre-operative IL-4 (P = 0.005, Figure 3C ) expression was decreased in RASP patients compared with non-RASP patients. As for pre-operative IL-1β (P = 0.773, Figure 3B ), IL-8 (P = 0.300, Figure 3E ), and IL-10 (P = 0.466, Figure 3F ) expressions, there was no difference between RASP patients and non-RASP patients.
| Analysis of inflammatory cytokines affecting RASP risk
Univariate logistic regression analysis was conducted to investigate the inflammatory cytokines affecting RASP risk, which disclosed that pre-operative TNF-α (P < 0.001), IL-6 (P < 0.001), IL-17A (P = 0.008), IL-21 (P = 0.015), and IL-23 (P < 0.001) were correlated with increased RASP risk, while pre-operative IL-4 (P = 0.017) expression was associated with declined RASP risk. In addition, hypertension (P = 0.009), SUA (P = 0.001), HsCRP (P < 0.001), neutrophil (P = 0.036), and multivessel artery lesions (P < 0.001) were correlated with increased RASP risk, Forward stepwise multivariate logistic regression analysis was further performed, which showed that pre-operative TNF-α (P = 0.003), IL-6 (P < 0.001), and IL-23 (P = 0.001) expressions were independent risk factors for RASP (Table 3 ). Hypercholesteremia (P = 0.021), SUA (P = 0.011), HsCRP (P < 0.001), and multivessel artery lesions (P = 0.006) could also independently predict RASP risk (Table 3 ).
| Predicting values of pre-operative TNF-α, IL-6, IL-21, and IL-23 expressions for RASP risk
To further explore the predicting values of TNF-α, IL-6, IL-23, hypercholesteremia, SUA, HsCRP, and multivessel artery lesions for RASP risk, 
| D ISCUSS I ON
Restenosis is characterized by the gradual re-narrowing of a stented coronary artery lesion owing to the arterial damage and the neointimal tissue proliferation. 5, 15 According to a previous study, restenosis occurs in about 30% of CAD patients underwent PCI with bare-metal stents. 5, 6 In recent years, DES has been invented and become more and more popular due to the better treatment efficacy and the lower the complication rate compared with bare-metal stents. 16 However, about 20% of CAD patients still occur restenosis after 2 years of PCI with DES. 17 In addition, a meta-analysis of 11 randomized clinical trials displays that the angiographic restenosis rate is 8.9% for drug-eluting stents within 1 year, while the restenosis rate was about 25% in this study, which was relatively higher compared with these previous studies. 18 The possible reasons were that (a) CAD patients enrolled in these 11 randomized clinical trials were less severe, and their disease severity (such as the length of target lesion) was lighter compared with our study. For instance, the length of target lesion ranged from 9.6 to 14.9 mm in these previous studies, while it was nearly 35.00 mm in this study.
Considering relatively longer length of target lesion meant worse disease conditions, the restenosis rate was relatively high in CAD The development and progression of restenosis is reported to be closely correlated with inflammatory activities in endothelial cells, while the predictive value of specific inflammatory factors for risk of restenosis is poorly understood. 2, 7 Just a previous study discloses that HsCRP could predict the elevated restenosis risk in CAD patients underwent PCI with DES. 2, 7 For inflammatory cytokines (the most common inflammatory proteins), they have been discovered to promote the formation of coronary artery lesion and the proliferation of neointimal tissue in CAD patients via multiple functions (such as recruit leukocytes to intima, facilitate the transformation of macrophages to foam cells, and promote the proliferation/migration of smooth muscle cells to the intima). 2, 19, 20 Besides, a few previous studies also observe that several inflammatory cytokines (such as IL-6 and TNF-α) are associated with increased CAD risk. 21, 22 Considering all the aforementioned evidences, we hypothesized that some specific inflammatory cytokines might also be associated with risk of restenosis in CAD patients underwent PCI with DES. 7 In addition, based on accu- expression might be associated with decreased restenosis risk. To further explore the predicting values of these inflammatory cytokine expressions for restenosis risk, logistic regression analysis was performed and then ROC curves were drawn. These analyses revealed that pre-operative IL-6 and IL-8 expressions were independent risk factors for restenosis, and they disclosed predicting values for restenosis risk with AUCs more than 0.6; more importantly, when combining IL-6, IL-8, hypercholesteremia, diabetes mellitus, and HsCRP, the AUC for predicting restenosis risk was more than 0.9. The possible reasons for the results might be as follows: IL-6 and IL-8 were able to deteriorate disease conditions of CAD patients underwent PCI with DES via multiple effects (such as increased endothelial cell expression of adhesion molecules, activated the macrophages, increased metalloprotease expressions, and mediated the detrimental effects of angiotensin II to the vessels); therefore, the higher pre-operative expressions of IL-6 and IL-8 predicted the increased risk of restenosis in CAD patients underwent PCI with DES. 2, 26, 27 Rapid angiographic stenotic progression is another common complication in CAD patients underwent PCI with DES, which strikingly affects the treatment efficacy of PCI with DES. 7, 28 Therefore, it is also crucial to investigate the biomarkers for predicting RASP risk.
Considering the predicting values of some inflammatory cytokines for cardiovascular disease risk including restenosis as aforementioned, we hypothesized that a series of inflammatory cytokines might also be associated with increased RASP risk. However, the relevant information is limited. Therefore, we also compared the expressions of inflammatory cytokines between RASP patients and non-RASP patients and found that pre-operative TNF-α, IL-6, IL-17A, IL-21, and IL-23 expressions were increased, whereas pre-operative IL-4 expression was decreased in RASP patients compared with non-RASP patients, implying that the pre-operative TNF-α, IL-6, IL-17A, IL-21, and IL-23 expressions might be associated with elevated RASP risk while pre-operative IL-4 expression might be correlated with reduced RASP risk. In addition, we also observed that pre-operative TNF-α, IL-6, and IL-23 expressions were independent risk factors for RASP, and they predicted RASP risk with AUCs more than 0.6; more interestingly, when combining TNF-α, IL-6, IL-23 hypercholesteremia, SUA, HsCRP, and multivessel artery lesions, the AUC for predicting RASP risk was over 0.8. In brief, our study facilitated the discovery of novel and convincing biomarkers for predicting restenosis and RASP risk in CAD patients underwent PCI with DES.
There remained some limitations in this study. Firstly, the sample size of restenosis patients was not matched with that of non-restenosis patients (due to the relatively low incidence of restenosis in CAD patients underwent PCI with DES), which might decrease the statistical power. Secondly, we compared the pre-operative expressions of nine common inflammatory cytokines between restenosis patients and non-restenosis patients, and between RASP patients and non-RASP patients, while the comparisons of other inflammatory cytokines between these patients needed additional investigations. Finally, the molecular mechanisms of these inflammatory cytokines in regulating restenosis and RASP were also required further explorations.
In summary, pre-operative IL-6 and IL-8 present with acceptable value for predicting restenosis risk; meanwhile, pre-operative TNF-α, IL-6, and IL-23 exhibit favorable value for predicting RASP risk in CAD patients underwent PCI with DES.
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